

# CURRICULUM VITAE

**Name:** LEENHARDT  
**First Name:** Laurence  
**Birth Date:** July 3, 1958  
**Title and Affiliation:** Medical Doctor, PhD in Human Sciences  
Professor of Endocrinology  
Department of Nuclear Medicine  
Groupe Hospitalier Pitié Salpêtrière, Paris VI University  
France

**Office Address:** Thyroid and Endocrine Tumors Unit, Department of Nuclear  
Medicine, Pitié Salpêtrière Hospital  
83 Bd de l'Hôpital, 75013 Paris, France  
Phone: +33 1 42 17 62 87 or 62 81  
Mobile Phone: +33 6 29 23 50 31  
Fax: +33 1 42 17 62 92  
Email: laurence.leenhardt@psl.aphp.fr

**Registration Number at Ordre des Médecins : 75/50522**

## Education:

**1984** M.D., (Thesis) Medical School Paris VII with honors,  
**1994** Nominated Hospital Practitioner,  
**1999** School of Public Health : Clinical protocols : methods and applications,  
**1999 – 2000** Diplôme d'Etudes Approfondies (DEA) : Demography, Dynamics and Biology  
of human populations. University Paris I Panthéon-Sorbonne: « Mortality of  
differentiated thyroid carcinoma »,  
**2001 – 2005** PhD thesis in Human Sciences, option : Demography (Université Paris I  
Panthéon Sorbonne). « Thyroid carcinoma and medical practice : measures  
and indicators ». Thesis advisors : Pr M. Schlumberger and Pr B Grossat,  
**2003-2004** University degree in medical pedagogy, University Paris VI,  
Certified to practice Endocrinology and Nuclear medicine,  
**2006** Certified to manage and supervise research, University Paris VI,  
**2009** University degree in Ultrasonography, Université Paris V.

**Speciality:** Endocrinology, **Sub speciality:** Nuclear medicine. **Special expertise in thyroid fields:**  
thyroid nodules, thyroid cancer, hyperthyroidism, hypothyroidism, thyroid biopsy, thyroid diseases,  
hyperparathyroidism

Dr Laurence Leenhardt is an endocrinologist in the Department of Nuclear Medicine at Pitié Salpêtrière Hospital, Paris, France. Dr Leenhardt is an MD with a PhD in Human Sciences. She is a Professor of Endocrinology and teaches at Pierre et Marie Curie University, Paris VI, France.

## 1. Hospital Medical Care

She is in charge of the Thyroid and Endocrine Tumors Unit at the Pitié Salpêtrière Hospital, Paris, France where she manages:

### 1.1. Thyroid nodules and cancers:

- Oversees a yearly average of 2700 sonographic examinations, 600 scintigraphic evaluations and 900 ultrasound guided aspirations for cytology,
- Follows up a cohort of patients presenting with thyroid cancer (9000 patients to this day),
- Manages a yearly average of 780 cases of differentiated thyroid cancer (initial treatment, radioiodine ablation and follow up) and a cohort of medullary thyroid cancers,

- Works in the nuclear imaging department: SPECT-CT hybrid imaging and FDG PET scan
- Conducts phase II and III clinical trials on HIFU treatment of thyroid nodules, elastography of thyroid nodules, and molecular markers, molecular therapies with ITK,
- Manages patients with refractory and progressive metastatic thyroid cancer,
- Belongs to the French Tumeurs de la Thyroïde Réfractaire (TUTHYREF) network.

### 1.2. Dysthyroidism:

Manages all causes of hyperthyroidism, radioiodine treatment of hyperthyroidism, hypothyroidism. Manages Grave's ophthalmopathy in collaboration with the 15/20 Hospital, Dr Laurence Dupasquier Fediaevsky in accordance with EUGOGO guidelines.

1.3. Primary hyperparathyroidism and multiple endocrine neoplasia: diagnosis, imaging MIBI scintigraphy, ultrasonography of parathyroid glands, adrenal scintigraphy.

## 2. Pedagogical contributions

Pr Leenhardt is the director of the national Thyroid Ultrasound degree course: « Diplôme National Inter Universitaire d'Echographie ». Her department organizes annual courses for students interested in thyroid and parathyroid ultrasonography. She is involved in the organization of the European US course at the ITC, ETA and ECE congresses. She has published chapters in specialized books on ultrasonography and written articles on ultrasonography and FNAB.

## 3. Thyroid research

The themes of Dr Leenhardt's research focus on 3 topics:

### 3.1. Research on thyroid carcinomas

- Fundamental biological molecular research on thyroid carcinoma: evaluation of prognostic factors in thyroid carcinoma.
- Clinical research: Involvement in several clinical protocols with ITK (Phase II and III):

### 3.2. Public health

She contributes to setting up guidelines at a national level:

- French guidelines for the management of patients with thyroid cancer,
- French guidelines for the management of patients with refractory thyroid cancer
- French guidelines for the management of patients with thyroid nodules.
- European Thyroid Association guidelines for cervical ultrasound scan and ultrasound - guided techniques in the postoperative management of patients with thyroid cancer

From 2000 to 2003, at the request of the French Department of Health, she chaired a multidisciplinary Thyroid Cancer Committee at the French Public Health Agency and in 2003 published guidelines for a national epidemiological surveillance system of thyroid cancer in France.

L. Leenhardt, April 2013 - 2 –

### 3.3. Thyroid imaging

She is a member of the INSERM unit (U 678) LIF: PI of clinical protocols:

- Elastography on patients with thyroid nodules presenting with indeterminate cytologies (supported by Super Sonic Imagine, Aix en Provence, France), ongoing,
- High intensity focused ultrasound treatment of thyroid nodules (HIFU): PI of randomized clinical trials on HIFU treatment of thyroid nodules (supported by Theraclion, Paris France).

### 4. Publications and Reviewerships

Dr Leenhardt is a member of the European Thyroid Association, of the French Endocrine Society, of the French Thyroid Research Group, of the French Endocrine Tumor Group, of the American Thyroid Association and of the Endocrine Society. She has written for the Journal of Clinical Endocrinology and Metabolism, the Thyroid and European Journal of Endocrinology. She is reviewer of various articles in the Journal of Endocrinology and Metabolism, the European Journal of Endocrinology, the European Journal of Cancer, European Journal of Radiology, Endocrine Connections, Thyroid.

Last publications in refereed journals (2011-2013):

1. **Leenhardt L.** F. Borson-Chazot M. Calzada, B. Carnaille, A. Charrié, B. Cochand-Priollet, C. Do Cao, S. Leboulleux, G. Le Clech, G. Mansour, F. Menegaux, H. Monpeyssen, J. Orgiazzi, A. Rouxel, JL. Sadoul, M. Schlumberger, J. Tramalloni, F. Tranquart, JL. Wemeau Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. *Ann Endocrinol* 2011; 72: 173–197.
2. **Leenhardt L.** Grosclaude P. Epidemiology of thyroid cancer over the world. *Ann Endocrinol* 2011; 72:136-148.
3. Slman R, Monpeyssen H, Desarnaud S, Haroche J, Fediaevsky LD, Fabrice M, Seret-Begue D, Amoura Z, Aurengo A, **Leenhardt L.** Ultrasound, Elastography, and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Riedel's Thyroiditis: Report of Two Cases. *Thyroid* 2011; Volume 21, Number 7 (Epub ahead of print) DOI: 10.1089/thy.2010.0242.
4. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, **Leenhardt L.** Schwartz C, Dejux C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. *J Clin Endocrinol Metab* 2011; 96:1352-1359.
5. Esnault O, Franc B, Menegaux F, Rouxel A, De Kerviler E, Bourrier P, Lacoste F, Chapelon JY, **Leenhardt L.** High Intensity focused ultrasound (HIFU) ablation of thyroid nodules : first human feasibility study. *Thyroid* 2011 21(9):965-73.
6. Wémeau JL, Sadoul JL, D'herbomez M, Monpeyssen H, Tramalloni J, Leteurtre E, Borson-Chazot F, Caron P, Carnaille B, Léger J, Do Cao C, Klein M, Raingeard I, Desailoud R, **Leenhardt L.** Guidelines of the French Society of Endocrinology for the management of thyroid nodules. *Ann Endocrinol* 2011 76 : 251-281.

7. Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, Mouawad R, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. *Med Oncol* 2012; Volume 29, Issue 3, p 1421-1428.
8. Wémeau JL, Sadoul JL, d'Herbomez M, Monpeyssen H, Tramalloni J, Leteurtre E, et al. Recommendations de la Société française d'endocrinologie pour la prise en charge des nodules thyroïdiens. *Presse Med* 2011;40:793-826.
9. Noullet S, Tresallet C, Godiris-Petit G, Hoang C, **Leenhardt L**, Menegaux F. Surgical management of sporadic medullary thyroid cancer. *J Visc Surg* 2011 148 (4) 244-249.
10. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, **Leenhardt L**, Bastie D, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejoux C, Toubert ME, Leboulleux S, Ricard M, Benhamou E. Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid. *N Engl J Med* 2012;366:1663-73.
11. Buffet C, Golmard JL, Hoang C, Trésallet C, Du Pasquier Fédiaevsky, Fierrard H, Aurengo A, Menegaux F, **Leenhardt L**. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. *European Journal of Endocrinology* 2012 ; 167 : 267–275
12. Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, **Laurence Leenhardt**, Christine Soufflet, Muriel Licour, Martin J Schlumberger. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind Phase II trial. *Lancet Oncology* 2012 Sep;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2. Epub 2012 Aug 14.
13. Russ G, Royer B, Bigorgne C, Rouxel A, Bienvenu M, **Leenhardt L**. *Eur J Endocrinol*. 2013 Feb 15. [Epub ahead of print].
14. Ducoudray R, Trésallet C, Godiris-Petit G, Tissier F, Leenhardt L, Menegaux F. Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? *World J Surg*, 2013, in press.
15. L. Leenhardt, M.F. Erdogan, L. Hegedus, S.J. Mandel, R. Paschke, T. Rago, G. Russ. European Thyroid Association guidelines for cervical ultrasound scan and ultrasound - guided techniques in the postoperative management of patients with thyroid cancer, *European Thyroid Journal*, 2013, in press.

#### **Appointments in societies and review boards:**

Member of the Ex Com of the European Thyroid Association (ETA) elected in 2011  
Member of the French Endocrine Society (SFE) (ex tresorer), French Thyroid Research Group (GRT), French Endocrine Tumors Group (GTE), European Society of Endocrinology, American Thyroid Association (ATA) and Endocrine Society.

Leenhardt Laurence

10 avril 2013

## Déclaration d'intérêt

Je, soussignée, Laurence Leenhardt

Nom : LEENHARDT

Prénom : Laurence

Numéro de téléphone : 01 42 17 62 87

Adresse électronique : laurence.leenhardt@psl.aphp.fr

Déclare par le présent document, qu'à ma connaissance, les seuls intérêt directs ou indirects que j'ai dans une entreprise ou un organisme susceptible d'intervenir dans domaines de la santé sont ceux listés ci-dessous :

### 1) Participation financière au capital d'une entreprise, d'une association ou de tout autre organisme.

Néant

entreprise / organisme : Dénomination .....  
Secteur d'activité .....

### 2) Activité(s) professionnelle(s) exercées personnellement

- **Activité professionnelle principale** : Praticien Hospitalier PUPH Service de Medecine Nucléaire, Endocrinologue.....,

exercée au sein de l'hôpital Pitié Salpêtrière

Position dans l'entreprise (propriétaire, dirigeant, salarié, associé, participation à un organe décisionnel) :.....

Nature du contrat : salarié APHP

exercée à titre de profession libérale .....

### - Autres activités régulières

lien(s) durable(s) ou permanents,

Contrat de travail (autre que l'activité professionnelle principale);

Activité de consultant : 0

Rémunération : 0

Participation à une instance d'un organisme (conseil d'administration, conseil scientifique...)

Conseil scientifique Club Thyroïde Merck Serono

Conseil scientifique IUC Institut Universitaire du Cancer

intervention(s) ponctuelle(s)

Participation à l'élaboration de rapports d'expertise

InVS, INCa, INSERM, PHRC, Genzyme

- Conférences, actions de formation, etc.

- .....
- Activité de conseil

...Genzyme.....

- Essais cliniques et travaux scientifiques

AstraZeneca, Bayer, Eisai, Theraclion, Diachonit

- Autre (ex. participation financière d'un organisme sous la forme d'une prise en charge de frais de participation à un congrès...);

Merck Serono, Genzyme

### 3) Autre(s) lien(s)

- parent(s) salarié(s) d'un organisme dont l'activité entre dans le champ des missions de l'InVS

Préciser l'organisme, le type de parenté (conjoint, enfant, frère, soeur...) et les fonctions du parent ...0

- Autres (participation à un conseil d'administration, un conseil scientifique ou une instance équivalente, activités au sein d'une association, d'un syndicat professionnel...).....0.....

### 4) Versements substantiels au budget d'une institution dont vous êtes responsable (depuis les 3 dernières années)

- organisme contributeur :
- objet du versement :
- institution bénéficiaire :
- date :

Je certifie par la présente avoir fait état de tous les intérêts directs ou indirects susceptibles de porter atteinte à l'objectivité dont je dois faire preuve dans le cadre de mes fonctions.

Je m'engage à déclarer tous autres intérêts que ceux ci-dessus énumérés que je viendrais à détenir dans l'avenir.

Fait à : Paris ; Le: 9 octobre 2013

Signature Leenhardt